BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has announced a poster presentation at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. The event will take place from November 8–10, 2024, at the George R. Brown Convention Center in Houston, TX.
The presentation, titled 'Updated results from a phase 1 study of evalstotug (BA3071), an anti-CTLA-4 conditionally active biologic, with or without nivolumab, in advanced solid tumors', is scheduled for Friday, November 8, 2024, at 9:00a CDT in Exhibit Halls AB. The presentation materials will be available on the 'Publication' section of BioAtla's website after the presentation concludes.
BioAtla, Inc. (Nasdaq: BCAB), una società biotecnologica globale in fase clinica focalizzata sullo sviluppo di terapie anticorpali biologiche (CAB) attive condizionatamente per il trattamento dei tumori solidi, ha annunciato una presentazione di poster al 39° Congresso Annuale della Society for Immunotherapy of Cancer (SITC). L'evento si svolgerà dall'8 al 10 novembre 2024, al George R. Brown Convention Center di Houston, TX.
La presentazione, intitolata 'Risultati aggiornati di uno studio di fase 1 su evalstotug (BA3071), un biologico attivo condizionatamente anti-CTLA-4, con o senza nivolumab, in tumori solidi avanzati', è programmata per venerdì 8 novembre 2024, alle 9:00 CDT nelle Sale Espositive AB. I materiali della presentazione saranno disponibili nella sezione 'Pubblicazioni' del sito web di BioAtla dopo la conclusione della presentazione.
BioAtla, Inc. (Nasdaq: BCAB), una compañía biofarmacéutica global en etapa clínica enfocada en desarrollar terapias anticuerpos biológicos activas condicionalmente (CAB) para el tratamiento de tumores sólidos, ha anunciado una presentación de cartel en el 39° Congreso Anual de la Sociedad para la Inmunoterapia del Cáncer (SITC). El evento se llevará a cabo del 8 al 10 de noviembre de 2024, en el George R. Brown Convention Center en Houston, TX.
La presentación, titulada 'Resultados actualizados de un estudio de fase 1 de evalstotug (BA3071), un biológico activamente condicional anti-CTLA-4, con o sin nivolumab, en tumores sólidos avanzados', está programada para el viernes 8 de noviembre de 2024, a las 9:00 a. m. CDT en los Salones de Exposición AB. Los materiales de la presentación estarán disponibles en la sección 'Publicaciones' del sitio web de BioAtla después de que se concluya la presentación.
BioAtla, Inc. (Nasdaq: BCAB)는 고형 종양 치료를 위한 조건부 활성 생물학적 CAB 항체 치료제를 개발하는 글로벌 임상 단계 생명공학 회사로서 암 면역요법 학회(SITC) 제39회 연례 회의에서 포스터 발표를 발표했습니다. 이 행사는 2024년 11월 8일부터 10일까지 텍사스 휴스턴의 조지 R. 브라운 컨벤션 센터에서 진행됩니다.
‘nivolumab 유무에 따른 고형 종양의 조건부 활성 생물학적 항체인 evalstotug (BA3071)의 1상 연구 업데이트 결과’라는 제목의 발표는 2024년 11월 8일 금요일 오전 9:00 CDT에 전시홀 AB에서 예정되어 있습니다. 발표 자료는 발표 종료 후 BioAtla 웹사이트의 '발표' 섹션에서 제공될 예정입니다.
BioAtla, Inc. (Nasdaq: BCAB), une entreprise biopharmaceutique mondiale en phase clinique axée sur le développement de thérapies anticorps biologiques (CAB) activées de manière conditionnelle pour le traitement des tumeurs solides, a annoncé une présentation de poster lors de la 39e Réunion Annuelle de la Society for Immunotherapy of Cancer (SITC). L'événement se tiendra du 8 au 10 novembre 2024, au George R. Brown Convention Center à Houston, TX.
La présentation, intitulée 'Résultats mis à jour d'une étude de phase 1 d'evalstotug (BA3071), un biologique activement conditionnel anti-CTLA-4, avec ou sans nivolumab, dans les tumeurs solides avancées', est prévue pour le vendredi 8 novembre 2024, à 9h00 CDT dans les Halles d'Exposition AB. Les documents de présentation seront disponibles dans la section 'Publications' du site web de BioAtla après la conclusion de la présentation.
BioAtla, Inc. (Nasdaq: BCAB), ein globales biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von bedingt aktiven biologischen (CAB) Antikörpertherapeutika zur Behandlung solider Tumoren konzentriert, hat eine Posterpräsentation auf dem 39. Jahreskongress der Society for Immunotherapy of Cancer (SITC) angekündigt. Die Veranstaltung findet vom 8. bis 10. November 2024 im George R. Brown Convention Center in Houston, TX statt.
Die Präsentation mit dem Titel 'Aktualisierte Ergebnisse einer Phase-1-Studie zu evalstotug (BA3071), einem bedingt aktiven biologischen Anti-CTLA-4, mit oder ohne Nivolumab, bei fortgeschrittenen soliden Tumoren' ist für Freitag, den 8. November 2024, um 9:00 Uhr CDT in den Ausstellungshallen AB geplant. Die Präsentationsmaterialien werden nach Abschluss der Präsentation im Abschnitt 'Veröffentlichungen' auf der Website von BioAtla verfügbar sein.
- BioAtla will present updated results from a phase 1 study of evalstotug (BA3071) at a major cancer conference
- The study investigates a potentially innovative treatment for advanced solid tumors
- None.
SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX.
Presentation Details:
| Title: | Updated results from a phase 1 study of evalstotug (BA3071), an anti-CTLA-4 conditionally active biologic, with or without nivolumab, in advanced solid tumors | |
| Authors: | Jacob Thomas, Eva Selfridge, Costantine Albany, Matthew H. Taylor, Inderjit Mehmi, Vineet Kwatra, Siwen Hu-Lieskovan, Paul De Souza, Ankit Mangla, Judith Llorin-Sangalang, Kartik Aysola, Omid Hamid | |
| Abstract Number: | 497 | |
| Date & Time: | Friday, November 8, 2024, 9:00a CDT | |
| Location: | Exhibit Halls AB | |
A copy of the presentation materials can be accessed on the “Publication” section of the Company’s website at www.bioatla.com once the presentation has concluded.
About BioAtla®, Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with greater than 765 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. The company’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. To learn more about BioAtla, Inc. visit www.bioatla.com.
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
External Contact:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
FAQ
When and where will BioAtla (BCAB) present its poster at the SITC Annual Meeting?
What is the title of BioAtla's (BCAB) poster presentation at the SITC Annual Meeting?
Where can investors find BioAtla's (BCAB) presentation materials after the SITC Annual Meeting?
